Clinical trials: Drug Mechanism
Acute Ischemic Stroke
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
Single-chain urokinase-type plasminogen activator (pro-urokinase) is a highly effective thrombolytic drug. At pharmacologic concentrations however, pro-urokinase is converted to urokinase - a non specific thrombolytic, limiting…
- Trial name
- NCT01694381
- Testing
- M5, C1-inhibitor
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- TSI, LLC
Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935
The purpose of this study is to determine the brain cholesterol 24S-hydroxylase (CH24H) enzyme occupancy of TAK-935 after single oral dose in healthy participants using the positron emission tomography (PET) ligand [18F]MNI-792…
- Trial name
- NCT02497235
- Testing
- TAK-935, [18F]MNI-792 (tracer)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
Neuropathic Pain
'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
Introduction Treatment of neuropathic pain has been a goal of numerous research projects for the last half century, with overall disappointing results.
- Trial name
- 0381-16 (NCT03276689)
- Testing
- Duloxetine, Pregabaline
- Where
- Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Drug Mechanism
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects
Psychiatric disorders often result from dysregulation in cellular and molecular mechanisms at the level of the brain. Unable to directly study brain tissues in patients affected by psychiatric conditions, researchers have created…
- Trial name
- NCT01565759
- Testing
- Lithium Carbonate
- Where
- Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Healthy
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262
- Trial name
- NCT05763459
- Testing
- ABBV-CLS-7262
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Calico Life Sciences LLC
Periodontal Pocket
The Proposed Study Aims to Investigate the Impact of Adjunctive Vitamin D Gel Application on Gingival Crevicular Fluid Levels of Alkaline Phosphatase and Interleukin-8 in Periodontitis Patients Undergoing Phase 1 Periodontal Therapy. By Elucidating the Molecular Mechanisms Underlying the Therapeutic
The proposed study aims to investigate the impact of adjunctive vitamin D gel application on gingival crevicular fluid levels of alkaline phosphatase and interleukin-8 in periodontitis patients undergoing phase 1 periodontal…
- Trial name
- NCT06669026
- Testing
- vitamin D loaded Poly lactic-co-glycolic acid nanoparticles gel, vitamin D3 gel (regular non-nanoparticle form), only mechanical debridement
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Type 2 Diabetes Mellitus
A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)
This is a study to assess the pharmacokinetics, safety, and tolerability of sequential single oral doses of MK-8093 10 mg, 40 mg, 200 mg, or placebo to MK-8093 (Part 1) depending on treatment assignment in young healthy male…
- Trial name
- NCT02012166
- Testing
- MK-0893 10 mg, MK-0893 40 mg, MK-0893 200 mg
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
A Relative Bioavailability Food Effect Study of LY03005
The objective if this study is to assess the relative bio-availability of single oral doses of 80 mg LY03005 tablets administered to healthy subjects under fed versus fasted conditions in a 2-period, crossover trial.
- Trial name
- NCT03822065
- Testing
- LY03005
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Child Growth, Diversity of Microbiome
MORDOR II Burkina Faso: Longitudinal Trial
Globally, childhood mortality has shown a promising downward trend in recent years, however, many sub-Saharan countries still have relatively high child mortality rates.
- Conditions
- Child Growth, Diversity of Microbiome, Child Mortality, Resistance Bacterial
- Trial name
- GAMIN (NCT03676751)
- Testing
- Azithromycin
- Where
- Burkina Faso
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Schizophrenia
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
This application seeks renewed support for MH59803, "Dopaminergic substrates of startle gating across species," to extend a clear path of "bench-to-bedside" progress towards a critical paradigm shift in therapeutic models for…
- Trial name
- NCT02634684
- Testing
- Dextroamphetamine
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Migraine
Effectiveness and Neural Mechanism of Naoan Dripping Pills for Migraine
This is a randomized, double-blind, placebo-controlled clinical trial. Its main purpose is to investigate the effects and neural mechanism of Naoan dripping pills on migraine patients by utilizing fMRI and DTI method, as well as…
- Trial name
- ENMNM (NCT03175900)
- Testing
- Naoan dripping pills
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Dongzhimen Hospital, Beijing
Immune Response
KLH Challenge to Explore the Human Immune Response
One approach to improve the efficiency of the drug development process is the use of human 'immune challenge' studies. In these studies, healthy volunteers are given small amounts of substances which are foreign to their immune…
- Trial name
- NCT05876195
- Testing
- Keyhole-Limpet Hemocyanin, Saline, Montanide ISA 51 VG
- Where
- United Kingdom
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Multiple Drug Use
Brain Mechanisms of Reducing Polysubstance Use
The proposed study will test whether neurofeedback (NF) could optimize integrative body-mind training (IBMT) practice.
- Trial name
- NCT06324786
- Testing
- IBMT, NF
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Hereditary Angioedema (HAE)
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.
- Trial name
- NCT02045264
- Testing
- Icatibant (30 mg)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shire
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Parkinson Disease
Motor Training in PD
The purpose of this research study is to learn more about brain activity when individuals with and without Parkinson disease (PD) move their lower limbs.
- Trial name
- NCT02457832
- Testing
- Adapted Tango Dancing, Behavioral Control (BC) Condition
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Cocaine Use Disorder, Opioid Use Disorder
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
The overarching hypotheses of this protocol are that (1) persistent brain glutamate changes induced by chronic opioid use will exacerbate use of cocaine during opioid physical dependence and withdrawal and (2) n-acetylcysteine…
- Conditions
- Cocaine Use Disorder, Opioid Use Disorder, Stimulant Use Disorder
- Trial name
- BED IN 43 (NCT05610072)
- Testing
- n-acetylcysteine, Hydromorphone
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- William Stoops
Alcohol Use Disorder (AUD), Alcoholism
Assessing Habitual, Goal-Directed, and Pavlovian Influences in Alcohol Use Disorder
The first aim of this study is to establish the role of maladaptive reliance on habits for impaired control in addiction, employing a novel task - the Action-Sequence-Task (AST), which assesses interference between habitual and…
- Conditions
- Alcohol Use Disorder (AUD), Alcoholism, Substance Use Disorders
- Trial name
- ReCoDe (NCT06701500)
- Testing
- Pavlovian-to-instrumental transfer (PIT) paradigm, Action Sequence Task (AST), Basic psychological assessment (interview)
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Technische Universität Dresden
Healthy
Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness
Psilocybin (active compound of "magic mushrooms") is a prototypical psychedelic substance that acts via agonism on serotonin (5-HT) 2A receptors. Psilocybin is rapidly metabolized into its active metabolite psilocin.
- Trial name
- PDR (NCT06796361)
- Testing
- Ketanserin 40mg plus Psilocybin 40mg, 40mg Psilocybin, 20mg Psilocybin
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland